Inherited Cancer Early Diagnosis Study (ICED)
Research type
Research Study
Full title
Inherited Cancer Early Diagnosis (ICED) Study. Liquid biopsy screening for early diagnosis of cancers in patients with cancer-predisposition syndromes
IRAS ID
304173
Contact name
Angela George
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Cancer predisposition syndromes account for at least 10% of all adult cancers worldwide. There are more than 50 hereditary cancer-predisposition syndromes and for most of these conditions there are established surveillance guidelines which imply frequent clinical, laboratory and radiological studies. There is a real need for a quicker and easier screening tool which could diagnose a cancer in this population sooner than clinical or radiological signs.
The ICED study aims to identify a novel blood and/or urine-based biomarker which will detect cancer in patients who have a very high risk of developing a tumour during their lifetime due to their underlying genetic condition. These patients, diagnosed with Li Fraumeni, Lynch, Cowden or Peutz-Jeghers syndromes will be enrolled from specialist Cancer Genetics clinics or specialist gastrointestinal service within our hospital.This study will enrol patients over 20 years old, carriers of a pathogenic genetic variant, who haven’t been diagnosed with a cancer in their past and are under routine surveillance. Patients will undergo sequential blood and urine tests during a period of 12 months. After collection, their samples will be analysed in the Molecular Pathology centre where genetic and epigenetic analysis will be done.
REC name
London - Fulham Research Ethics Committee
REC reference
22/PR/0572
Date of REC Opinion
28 Jun 2022
REC opinion
Further Information Favourable Opinion